TrialJournal for immunotherapy of cancer2026
Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.
Jason Mark Redman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.